1. Home
  2. NUVB vs NPKI Comparison

NUVB vs NPKI Comparison

Compare NUVB & NPKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • NPKI
  • Stock Information
  • Founded
  • NUVB 2018
  • NPKI 1932
  • Country
  • NUVB United States
  • NPKI United States
  • Employees
  • NUVB N/A
  • NPKI N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • NPKI Metal Fabrications
  • Sector
  • NUVB Health Care
  • NPKI Industrials
  • Exchange
  • NUVB Nasdaq
  • NPKI Nasdaq
  • Market Cap
  • NUVB 1.1B
  • NPKI 881.5M
  • IPO Year
  • NUVB N/A
  • NPKI N/A
  • Fundamental
  • Price
  • NUVB $3.28
  • NPKI $10.76
  • Analyst Decision
  • NUVB Strong Buy
  • NPKI Strong Buy
  • Analyst Count
  • NUVB 6
  • NPKI 3
  • Target Price
  • NUVB $8.17
  • NPKI $12.17
  • AVG Volume (30 Days)
  • NUVB 6.7M
  • NPKI 664.3K
  • Earning Date
  • NUVB 11-05-2025
  • NPKI 11-06-2025
  • Dividend Yield
  • NUVB N/A
  • NPKI N/A
  • EPS Growth
  • NUVB N/A
  • NPKI N/A
  • EPS
  • NUVB N/A
  • NPKI N/A
  • Revenue
  • NUVB $14,355,000.00
  • NPKI $234,741,000.00
  • Revenue This Year
  • NUVB $332.80
  • NPKI $19.94
  • Revenue Next Year
  • NUVB $360.12
  • NPKI $9.36
  • P/E Ratio
  • NUVB N/A
  • NPKI N/A
  • Revenue Growth
  • NUVB 900.35
  • NPKI 6.96
  • 52 Week Low
  • NUVB $1.54
  • NPKI $4.76
  • 52 Week High
  • NUVB $4.09
  • NPKI $10.99
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 58.18
  • NPKI 65.88
  • Support Level
  • NUVB $3.20
  • NPKI $10.35
  • Resistance Level
  • NUVB $3.41
  • NPKI $10.75
  • Average True Range (ATR)
  • NUVB 0.27
  • NPKI 0.24
  • MACD
  • NUVB -0.03
  • NPKI -0.02
  • Stochastic Oscillator
  • NUVB 33.55
  • NPKI 73.30

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About NPKI NPK International Inc. Common Stock

NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.

Share on Social Networks: